Cargando…

Adjunctive Use of Circulating Tumor DNA Testing in Detecting Pancreas Cancer Recurrence

Liquid biopsies (circulating tumor DNA—ctDNA testing) are increasingly being utilized in clinical trials as well as practice for the detection of cancer, monitoring of tumor genomic abnormalities, response to treatment and early detection of relapse/recurrence. Here, we present a challenging case wh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soyano, Aixa E., Baldeo, Candice, Kasi, Pashtoon M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372543/ https://www.ncbi.nlm.nih.gov/pubmed/30788289 http://dx.doi.org/10.3389/fonc.2019.00046

Ejemplares similares

Neuroendocrine Tumor Involving the Epicardium
por: Soyano, Aixa E., et al.
Publicado: (2017)

Role of Circulating Tumor DNA in Gastrointestinal Cancers: Update From Abstracts and Sessions at ASCO 2018
por: Shahjehan, Faisal, et al.
Publicado: (2019)

Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge
por: Chennamadhavuni, Adithya, et al.
Publicado: (2022)

Circulating Tumor DNA-Based Detection of Microsatellite Instability and Response to Immunotherapy in Pancreatic Cancer
por: Kamatham, Saivaishnavi, et al.
Publicado: (2020)

Uridine triacetate for severe 5-fluorouracil toxicity in a patient with thymidylate synthase gene variation: Potential pharmacogenomic implications
por: Baldeo, Candice, et al.
Publicado: (2018)

Feasibility of Integrating Panel-Based Pharmacogenomics Testing for Chemotherapy and Supportive Care in Patients With Colorectal Cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2019)

Editorial: Case reports in gastrointestinal cancers : 2022
por: Kasi, Pashtoon Murtaza
Publicado: (2023)

Favorable Outcomes in FGFR Fusion-Positive Cholangiocarcinomas and Evolution on Treatment Noted on Circulating Tumor DNA Liquid Biopsies
por: Kasi, Pashtoon Murtaza
Publicado: (2020)

Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices
por: Malla, Midhun, et al.
Publicado: (2022)

Circulating Tumor DNA Response and Minimal Residual Disease Assessment in DNA Polymerase Epsilon-Mutated Colorectal Cancer Undergoing Immunotherapy
por: Lutfi, Areeb, et al.
Publicado: (2023)

Rifaximin for Pertuzumab-Related GI Toxicities
por: Soyano, Aixa E., et al.
Publicado: (2017)

Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer
por: Jiang, Jiahong, et al.
Publicado: (2020)

Postoperative circulating tumor DNA detection is associated with the risk of recurrence in patients resected for a stage II colorectal cancer
por: Grancher, Adrien, et al.
Publicado: (2022)

Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma
por: Yarlagadda, Bhavya, et al.
Publicado: (2019)

Circulating tumour cell enumeration, biomarker analyses, and kinetics in patients with colorectal cancer and other GI malignancies
por: Malkawi, Walla, et al.
Publicado: (2023)

Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients
por: Chan, Hiu Ting, et al.
Publicado: (2023)

Circulating Tumor DNA Analyses Predict Disease Recurrence in Non-Muscle-Invasive Bladder Cancer
por: Zhang, Jinghua, et al.
Publicado: (2021)

Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers
por: Huffman, Brandon M., et al.
Publicado: (2022)

Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma
por: Azzi, Georges, et al.
Publicado: (2022)

Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry Study
por: Wang, Cassia B., et al.
Publicado: (2019)

Incidence of Pathogenic Variants in Those With a Family History of Pancreatic Cancer
por: Macklin, Sarah K., et al.
Publicado: (2018)

Larotrectinib in Mismatch-Repair-Deficient TRK Fusion-Positive Metastatic Colon Cancer After Progression on Immunotherapy
por: Kasi, Pashtoon M, et al.
Publicado: (2022)

Circulating Tumor DNA Detection in the Management of Anti-EGFR Therapy for Advanced Colorectal Cancer
por: Knebel, Franciele H., et al.
Publicado: (2019)

Body Mass Index and Long-Term Outcomes in Patients With Colorectal Cancer
por: Shahjehan, Faisal, et al.
Publicado: (2018)

An Improved Detection of Circulating Tumor DNA in Extracellular Vesicles-Depleted Plasma
por: Sun, Li, et al.
Publicado: (2021)

Types of Liquid Biopsies: Understanding the Different Lenses Through Which They Can Detect Cancer
por: Kasi, Pashtoon Murtaza
Publicado: (2023)

The Use of Circulating Tumor DNA for Prognosis of Gastrointestinal Cancers
por: Saluja, Hariti, et al.
Publicado: (2018)

Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers
por: Hsiehchen, David, et al.
Publicado: (2022)

Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer
por: Fang, Xiaoxu, et al.
Publicado: (2022)

Postoperative circulating tumor DNA testing based on tumor naïve strategy after liver metastasis surgery in colorectal cancer patients
por: Jiang, Huiqin, et al.
Publicado: (2023)

Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy
por: Lin, Po-Han, et al.
Publicado: (2021)

Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers
por: Okuma, Hitomi Sumiyoshi, et al.
Publicado: (2021)

Circulating Tumor DNA Analyses as a Potential Marker of Recurrence and Effectiveness of Adjuvant Chemotherapy for Resected Non-Small-Cell Lung Cancer
por: Kuang, Peng-Peng, et al.
Publicado: (2021)

Author Correction: Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers
por: Hsiehchen, David, et al.
Publicado: (2023)

New Screening Test Improves Detection of Prostate Cancer Using Circulating Tumor Cells and Prostate-Specific Markers
por: Ried, Karin, et al.
Publicado: (2020)

The Mutational Landscape of Pancreatic and Liver Cancers, as Represented by Circulating Tumor DNA
por: Rice, Alistair, et al.
Publicado: (2019)

The Potential Clinical Utility of Circulating Tumor DNA in Esophageal Adenocarcinoma: From Early Detection to Therapy
por: Kosovec, Juliann E., et al.
Publicado: (2018)

Tumor-Informed Versus Plasma-Only Liquid Biopsy Assay in a Patient With Multiple Primary Malignancies
por: Kasi, Pashtoon Murtaza
Publicado: (2022)

Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients
por: Nguyen, Huu Thinh, et al.
Publicado: (2022)

Detection of Circulating Tumor Cells in Non-Small Cell Lung Cancer
por: Hanssen, Annkathrin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_j2sq3rprumvo06lo4jeijer9u0